GALT and classic galactosemia: In this study, we aimed to extend our earlier in vivo POC work for an experimental GALT mRNA therapy for classic galactosemia from disease-relevant [17] and functional biomarker [18] normalization to disease-relevant phenotypes correction in a mouse model of galactosemia.